Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 2Squamous Cell Carcinoma of Head and Neck 1Solitary Fibrous Tumors 1Sarcoma 1Ovarian Neoplasms 1Lung Neoplasms 1Liposarcoma 1Histiocytoma, Malignant Fibrous 1Fallopian Tube Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Dermatofibrosarcoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 18Paclitaxel 13Carboplatin 10Pemetrexed 4Cisplatin 4patritumab deruxtecan 3Gemcitabine 3Docetaxel 3Capecitabine 3Albumin-Bound Paclitaxel 3Histamine H2 Antagonists 2Histamine Antagonists 2Dexamethasone 2Acetaminophen 2130-nm albumin-bound paclitaxel 2trastuzumab deruxtecan 1osimertinib 1olaparib 1liposomal doxorubicin 1lenvatinib 1enzalutamide 1cemiplimab 1Vascular Endothelial Growth Factor A 1Serotonin 5-HT3 Receptor Antagonists 1Ramucirumab 1Oxaliplatin 1Neurokinin-1 Receptor Antagonists 1Neoadjuvant Therapy 1Levoleucovorin 1Leucovorin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Parkinson Disease 4, Autosomal Dominant Lewy Body × Histamine H2 Antagonists × Clear all
NCT06788912 2026-06-01

MK-3475-01E

Merck Sharp & Dohme LLC

Phase 2 Recruiting
60 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

NCT05319730 2026-05-26

MK-3475-06B

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
230 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡